A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis

Clinical trial NCT06410040 · UNKNOWN

Trial details

NCT number: NCT06410040
Sponsor: Sichuan Cancer Hospital and Research Institute
Status: UNKNOWN
Study type: OBSERVATIONAL

ALK-positive Non-small Cell Lung Cancer Brain Metastases Meningeal Metastasis

Start date: 2023-08-20
Primary completion: 2024-03-31
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.